SANUWAVE HEALTH REPORTS RECORD SECOND QUARTER REVENUE INCREASE AND SIGNIFICANT MILESTONES ACHIEVED DURING THE QUARTER Company expects continued growth in 2nd half of 2018 from product sales in US an

SANUWAVE HEALTH REPORTS RECORD SECOND QUARTER REVENUE INCREASE AND

SIGNIFICANT MILESTONES ACHIEVED DURING THE QUARTER

Company expects continued growth in 2nd half of 2018 from

product sales in US and International markets

SUWANEE, GA, August 14, 2018 SANUWAVE Health, Inc. (OTCQB:

SNWV) reported financial results for the three months

ended June 30, 2018 with the SEC on Tuesday, August 14, 2018 and

will provide a business update on a conference call today, August

14, 2018 at 10:00 a.m. Eastern Time.

Highlights of the second quarter and recent weeks:

revenue for the second quarter of 2018 was $453,210, up 308% from

the second quarter of 2017.

Company named Shri Parikh President of SANUWAVE's Global

Healthcare division.

The Company entered into an agreement with

( FKS ), pursuant to which the Company and FKS will

enter into a joint venture for the manufacture, sale and

distribution of the Company's dermaPACE

devices covering 11 countries in Southeast Asia. The initial payment per the agreement has been

received, initial orders have been shipped in Q3 and this agreement

is expected to drive significant growth in the near

Company signed a binding term sheet for a joint venture with

Tarbaca Lightning covering 3 countries in Central

Company appointed Dr. Perry Mayer, Medical Director and principal

at The Mayer Institute in Hamilton, Ontario, Canada, to its

Clinical Advisory Board.

Company appointed AMBIENSYS SRL as its distributor for dermaPACE in

Romania. The initial orders have been shipped and training

successfully occurred in Q2.

quarter medical conference attendance activity for the Company is

expected to be a record eight meetings.

case study kicked off in July with Rutgers, UCLA, and Northwestern

University. We anticipate full results from this clinical work to

be released in early 2019.

Since the FDA clearance, we have begun to develop and implement a

platform for rolling out the dermaPACE System

for treating DFU's in the US. We are taking a

methodical approach to the roll out to ensure we ultimately achieve

our goal - the delivery of a dermaPACE System to any location

in the US that will be treating DFU's. As we have stated

on prior calls, we have five goals for 2018 which will deliver

accelerating growth throughout the year and establish the platform

for continued growth in 2019 and beyond as we penetrate the US and

global wound care market. The goals for 2018

management team in U.S. wound market

international markets

of Directors and Science Advisory Board

We are well on track to achieve or exceed all the goals we

established for 2018 and this translates to revenue increases

throughout the year. As we hire experienced senior managers in the

areas of Reimbursement, Clinical, and Sales, we anticipate revenue

expansion occurring in the US toward the end of 2018 building a

strong foundation to deliver substantial domestic revenue in

Second Quarter Financial Results

three months June 30, 2018 were $453,210, compared to $111,045 for

the same period in 2017, an increase of $342,165, or 308%. Revenues

resulted primarily from sales in the United States and Europe of

our dermaPACE and orthoPACE devices and related applicators. The

increase in revenues for 2018 was due to the higher sale of devices

and both new and refurbished applicators in the United States and

Europe as compared to the same period in 2017.

development expenses for the three months ended June 30, 2018 were

$368,377, compared to $437,909 for the same period in 2017, a

decrease of $69,572, or 16%. The decrease in research and

development expenses was due to lower stock-based compensation

expense and to lower consultant costs related to the FDA submission

and follow up which was partially offset by the hiring of a

full-time software engineers and an accrual of bonus for

and administrative expenses for the three months ended June 30,

2018 were $2,030,799, as compared to $951,908 for the same period

in 2017, an increase of $1,078,891, or 113%. The increase in

general and administrative expenses was due to the hiring of a

president and human resources director and the related stock-based

compensation expense for stock options issued, higher travel costs,

accrual of bonus, higher public company costs related to investor

relations, higher costs related to leasing of product, and higher

consultant fees related to the commercialization of the dermaPACE

loss for the three months ended June 30, 2018 was $2,888,259, or

($0.02) per basic and diluted share, compared to a net loss of

$1,415,937, or ($0.01) per basic and diluted share, for the same

period in 2017, an increase in the net loss of $1,472,322. The

increase in the net loss for 2018 was primarily due to higher

general and administrative expenses as noted above as well as

higher interest expense related to convertible promissory notes

which was partially offset by gain on warrant valuation

anticipate that our operating losses will continue over the next

few years as we incur expenses related to commercialization of our

dermaPACE system for the treatment of diabetic foot ulcers in the

United States. If we are able to successfully commercialize, market

and distribute the dermaPACE system, we hope to partially or

completely offset these losses in the future.

Six Months ended June 30, 2018 Financial Results

six months June 30, 2018 were $797,482, compared to $260,614 for

the same period in 2017, an increase of $536,868, or 206%. Revenues

resulted primarily from sales in the United States and Europe of

our dermaPACE and orthoPACE devices and related applicators. The

increase in revenues for 2018 was due to the higher sale of devices

and both new and refurbished applicators in the United States and

Europe as compared to the same period in 2017.

development expenses for the six months ended June 30, 2018 were